Cancer diagnostics News and Research

RSS

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

A comprehensive study of the components of the delivery of modern-day cancer care in community oncology practices revealed that Medicare covers only 56% of the actual costs of administering chemotherapy and providing related infusion room services to seniors with cancer. The remaining costs -- for essential services provided such as treatment planning, care coordination, and follow-up care planning -- are not reimbursed by Medicare, causing many oncology practices to struggle to continue to provide care under the Medicare program.

5 Feb 2010

Regular exercise and drinking tea may reduce depression in breast cancer patients

Breast cancer patients who exercise and drink tea on a regular basis may be less likely to suffer from depression than other patients, according to a new study led by Xiao Ou Shu, M.D., Ph.D., professor of Medicine, Vanderbilt-Ingram Cancer Center. Xiaoli Chen, M.D., a post-doctoral fellow, was first author of the study published in the January issue of the Journal of Clinical Oncology.

28 Jan 2010

New research project aims at understanding the genetic origins of childhood cancers

St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world's deadliest childhood cancers.

27 Jan 2010

Biomoda applauds Senator for introducing legislative bill for lung cancer screening

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) today applauded Nebraska State Sen. Bob Krist and his co-sponsors for introducing legislation to screen up to 500 Nebraska veterans for early-stage lung cancer.

27 Jan 2010

Quest Diagnostics announces 2.8% increase in revenues for full-year 2009

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2009, income from continuing operations increased to $182 million, or $0.97 per diluted share, compared to $170 million, or $0.87 per diluted share, in 2008. The quarter included a $0.04 per share charge associated with the early extinguishment of debt, which was offset by certain non-recurring tax benefits totaling $0.04 per share.

From Quest Diagnostics 25 Jan 2010

Random lasers may prove useful for diagnosing cancer, say Utah researchers

When University of Utah scientists discovered a new kind of laser that was generated by an electrically conducting plastic or polymer, no one could explain how it worked and some doubted it was real.

24 Jan 2010

Ontario must stay the course in the fight against lung cancer

Currently an estimated 7,800 Ontarians are diagnosed with lung cancer and approximately 6,000 die of the disease each year. Smoking and exposure to second-hand smoke continue to be the main risk factors for developing lung cancer - and that is why we must continue to encourage Ontarians to be smoke-free.

21 Jan 2010

College of American Pathologists unveils resources and features on cancer in MyBiopsy.org

There's nothing more frightening than hearing the words "you have cancer" from your physician. With this diagnosis, many questions come to mind ... What's next? Will I survive? How do I tell my loved ones? The last is the most important for many people after receiving a cancer diagnosis: I need accurate information right now.

21 Jan 2010

AstraZeneca and Dako Denmark A/S enter into collaboration agreement

AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development.

18 Jan 2010

European approval for Abbott's new ovarian cancer diagnostic test

A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer.

14 Jan 2010

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

A $1 million grant from Abraxis Bioscience, Inc. to a world-famous research laboratory at John Wayne Cancer Institute at Saint John’s Health Center could help save lives of cancer patients by helping doctors more rapidly assess whether a treatment is working or not.

12 Jan 2010

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.

12 Jan 2010

Detroit paper explores pain of facing breast cancer without insurance

A woman with a $7,000 annual income and $67 in the bank was diagnosed with breast cancer, leading to a week of phone calls from her surgeon to state, federal and hospital officials before a charitable agreement was struck with a medical center, the Detroit Free Press reports.

12 Jan 2010

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

A new national survey reveals that while almost all Canadians understand the importance of getting checked for colon cancer, most have not had a screening test and are confused about how and when it should happen.

8 Jan 2010

OncoDiagnostic Laboratory acquired by Predictive Biosciences

Predictive Biosciences today announced that it has acquired Cleveland, Ohio based OncoDiagnostic Laboratory (“ODL”), a private, Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians nationwide.

7 Jan 2010

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, and Genetic Technologies Ltd. (ASX: GTG; NASDAQ: GENE), the leading private genetic testing laboratory in Australia, today announced an exclusive distribution and services agreement.

7 Jan 2010

Protective benefits of Alzheimer's and cancer may lead to new diagnostic treatments

People who have Alzheimer's disease may be less likely to develop cancer, and people who have cancer may be less likely to develop Alzheimer's disease, according to a new study published in the December 23, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Dec 2009

Arrayit achieves technological breakthrough in microarray production

Arrayit Corporation, a life sciences and healthcare technology leader, today announced that the Company has made a technological breakthrough in the speed and efficiency by which it manufactures its proprietary microarrays, which are tiny glass substrates that contain rows and columns of printed spots used for scientific research and molecular diagnostics.

22 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2009 and provided a business update.

18 Dec 2009

Cancer diagnostics News and Research

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

Regular exercise and drinking tea may reduce depression in breast cancer patients

New research project aims at understanding the genetic origins of childhood cancers

Biomoda applauds Senator for introducing legislative bill for lung cancer screening

Quest Diagnostics announces 2.8% increase in revenues for full-year 2009

Random lasers may prove useful for diagnosing cancer, say Utah researchers

Ontario must stay the course in the fight against lung cancer

College of American Pathologists unveils resources and features on cancer in MyBiopsy.org

AstraZeneca and Dako Denmark A/S enter into collaboration agreement

European approval for Abbott's new ovarian cancer diagnostic test

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

Detroit paper explores pain of facing breast cancer without insurance

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

OncoDiagnostic Laboratory acquired by Predictive Biosciences

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Protective benefits of Alzheimer's and cancer may lead to new diagnostic treatments

Arrayit achieves technological breakthrough in microarray production

Clarient announces acquisition of Applied Genomics

Rosetta Genomics announces third-quarter 2009 financial results

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News